A physician-level review of real-world evidence for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including registry data, observational cohorts, and how RWE compares to RCT findings on NAD+ precursors.
NMN supplements sit in a legal gray zone: the FDA excluded NMN from the dietary supplement definition in 2022, and the EU and UK have not authorized it.
NMN at 40°C is not stable long-term: unprotected powder loses 15-30% potency over 6 months at 40°C/75% RH, the ICH accelerated stability test standard.
Evidence-based protocol for resuming nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) supplementation after acute illness, with dosing guidance, timing, contraindications, and the latest trial data.
Evidence-based guide to switching between nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and other NAD+ precursors, including dosing protocols, pharmacokinetic differences, and clinical considerations.